Robotic-assisted pancreatic surgery significantly reduces complications and improves recovery compared to laparoscopic methods. Conversion rates were lower in robotic cases (2.5% vs. 17.2%, p < 0.001). Blood loss was less with robotic surgery (119 ml vs. 179 ml, p = 0.013), and recovery time was faster (8.2 days vs. 9.6 days, p = 0.038). Robotic […]

In intraductal papillary mucinous neoplasm-derived pancreatic cancer, removing at least 20 lymph nodes dramatically improves survival outcomes. The minimum required for accurate staging is 10 lymph nodes (p=0.040). Optimal lymphadenectomy of 20 nodes leads to a median overall survival of 80.3 months compared to 37.2 months with fewer nodes (p<0.001). Prioritizing at least 20 lymph […]

Robotic liver resection offers advantages over laparoscopic approaches, especially with deeper transections. In deeper liver transections (>2.5 cm), robotic resection had a significantly shorter operative time (145 mins vs. 231 mins, p<0.001). Blood loss was less in robotic cases (nil vs. 100 ml, p=0.006) and led to better overall outcomes, with 76.7% achieving textbook results […]

Identifying residual disease in incidental gallbladder cancer is crucial for improving surgical outcomes. Residual disease was found in 36% of patients, significantly lowering recurrence-free survival (42 months vs. 11 months) and overall survival (60 months vs. 22 months). Key risk factors for residual disease include CA19-9 levels >39 U/ml, open cholecystectomy, and advanced tumor stages. […]

Liver resection combined with systemic therapy offers better survival for patients with hepatocellular carcinoma and macrovascular invasion. Overall survival rates at 1, 3, and 5 years post-resection were 65.9%, 37.7%, and 28.6%, vastly superior to 29.3%, 10.1%, and 5.4% in non-resection groups. Preoperative systemic therapy led to even higher survival rates: 81.2%, 50.0%, and 40.6% […]

PAXG shows superior efficacy over mFOLFIRINOX for patients with resectable pancreatic ductal adenocarcinoma. Median event-free survival (EFS) for PAXG is 16.0 months compared to 10.2 months for mFOLFIRINOX. EFS hazard ratio is 0.63, indicating a significant benefit for PAXG (p=0.0018). Surgeons should consider PAXG as the preferred preoperative chemotherapy regimen for this patient population. Adverse […]

Robotic-assisted and laparoscopic liver resection yield better outcomes for BCLC stage 0/A hepatocellular carcinoma compared to open surgery. Operative times were longer for robotic (225 min) and laparoscopic (225 min) than for open (170 min, p < 0.001). Postoperative complications were lower for robotic (12.5%) and laparoscopic (13.4%) versus open (17.1%, p < 0.001), with […]

This study develops and validates a prognostic model for patients with unresectable hepatocellular carcinoma treated with transcatheter arterial chemoembolization plus lenvatinib. Identified nine key risk factors impacting overall and progression-free survival, including tumor number and extrahepatic metastases. Survival prediction model showed area under the curve values of 0.706 at 3 years for overall survival and […]

Evaluating nutrition and body composition can enhance post-surgery success in pancreaticoduodenectomy. 57.2% of patients achieved a textbook outcome, with no 30-day mortality. Key risk factors for not achieving a textbook outcome include age ≥75, malnutrition, and a high visceral fat to muscle ratio. Focusing on these factors preoperatively may significantly improve patient outcomes and overall […]